# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 461-470 of 573 results.
A Study of PLX2853 in Advanced Malignancies.
Status: Recruiting
Last Changed: Jun 09, 2020
First Received: Sep 29, 2017
Disease(s): Small Cell Lung Cancer, Uveal Melanoma, Ovarian Clear Cell Carcinoma, Non-Hodgkin Lymphoma, Advanced Malignancies, Solid Tumor, Diffuse Large B Cell Lymphoma, Follicular Lymphoma
Intervention(s): PLX2853
Locations: Honor Health, Scottsdale, Arizona, United States
Sylvester Comprehensive Cancer Center / University of Miami Miller School of Medicine, Miami, Florida, United States
Columbia University Medical Center, New York, New York, United States
South Texas Accelerated Research Therapeutics (START), San Antonio, Texas, United States
Virginia Cancer Specialist, PC - Fania Picado, Fairfax, Virginia, United States
... and 1 other locations.
CD19-Specific T Cells Post AlloSCT
Status: Recruiting
Last Changed: Jul 24, 2020
First Received: Jul 09, 2018
Disease(s): B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Ph-Like Acute Lymphoblastic Leukemia, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Mantle Cell Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Ph-Like Acute Lymphoblastic Leukemia, Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Refractory Small Lymphocytic Lymphoma
Intervention(s): Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells, Cyclophosphamide, Fludarabine
Locations: M D Anderson Cancer Center, Houston, Texas, United States
IBI376 in Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma
Status: Recruiting
Last Changed: May 27, 2020
First Received: Mar 06, 2020
Disease(s): Indolent Non-hodgkin Lymphoma
Intervention(s): IBI376
Locations: Ruijin hospital, school of medicine, Shanghai jiao tong university, Shanghai, China
MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)
Status: Not yet recruiting
Last Changed: Oct 07, 2019
First Received: Oct 01, 2019
Disease(s): Follicular Lymphoma and Marginal Zone Lymphoma
Intervention(s): Recombinant Humanized Monoclonal Antibody MIL62 Injection, Lenalidomide
Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)
Status: Recruiting
Last Changed: Sep 21, 2020
First Received: Dec 07, 2018
Disease(s): Follicular Lymphoma (FL), Non Hodgkin Lymphoma, Marginal Zone Lymphoma
Intervention(s): Zandelisib (ME-401)
Locations: Oncology Institute of Hope and Innovation, Tucson, Arizona, United States
Pacific Cancer Medical Center, Inc., Anaheim, California, United States
The Oncology Institute of Hope and Innovation, Downey, California, United States
Sharp Memorial Hospital, San Diego, California, United States
H. Lee Moffit Cancer Center, Tampa, Florida, United States
... and 100 other locations.
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Status: Recruiting
Last Changed: Sep 07, 2020
First Received: Apr 07, 2017
Disease(s): Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-Hodgkin Lymphoma
Intervention(s): axicabtagene ciloleucel, Cyclophosphamide, Fludarabine
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
University of California Los Angeles, Los Angeles, California, United States
Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
University of Miami Hospital and Clinics, Miami, Florida, United States
... and 15 other locations.
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
Status: Recruiting
Last Changed: Oct 21, 2019
First Received: Sep 18, 2018
Disease(s): Acute Lymphoblastic Leukemia, Adult, Acute Lymphoblastic Leukemia, Pediatric, Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma
Intervention(s): CD19.CAR T Cells, Fludarabine, Cyclophosphamide
Locations: University Hospital Heidelberg, Heidelberg, Germany
University Hospital Heidelberg, Heidelberg, Germany
A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies
Status: Recruiting
Last Changed: Sep 25, 2020
First Received: Mar 22, 2019
Disease(s): Relapsed/Refractory Advanced Solid Tumors, Relapsed/Refractory Diffuse Large B-cell Lymphoma, Relapsed/Refractory Myelodysplasia, Relapsed/Refractory Myelofibrosis, Adenoid Cystic Carcinoma, Relapsed/Refractory Mantle Cell Lymphoma
Intervention(s): PRT543
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
Christiana Care Health Services, Christiana Hospital, Newark, Delaware, United States
Florida Cancer Specialists, Lake Mary, Florida, United States
Florida Cancer Specialist, Sarasota, Florida, United States
Norton Cancer Institute, St. Matthews Campus, Louisville, Kentucky, United States
... and 8 other locations.
Bispecific Antibody AFM13 Combined With NK Cells for Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas
Status: Recruiting
Last Changed: Aug 25, 2020
First Received: Aug 30, 2019
Disease(s): Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Recurrent Peripheral T-Cell Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, TNFRSF8 Positive
Intervention(s): Anti-CD30/CD16A Monoclonal Antibody AFM13, Cyclophosphamide, Fludarabine, Fludarabine Phosphate, Genetically Engineered Lymphocyte Therapy
Locations: M D Anderson Cancer Center, Houston, Texas, United States
CAR-37 T Cells In Hematologic Malignancies
Status: Recruiting
Last Changed: Jul 16, 2020
First Received: Oct 23, 2019
Disease(s): Hematologic Malignancy, Leukemia, Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Non-Hodgkin
Intervention(s): CAR-37 T cells
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States